Valuation: Innoviva, Inc.

Market Cap 148.1Cr 131.59Cr 122.82Cr 111.94Cr 211.13Cr 14TCr 213.09Cr 1.49TCr 575.94Cr 7.28TCr 556.05Cr 543.98Cr 23TCr P/E 2026 *
9.18x
P/E 2027 * 9.06x
Enterprise Value 96Cr 85Cr 79Cr 72Cr 136.15Cr 9.18TCr 137.42Cr 958.49Cr 371.42Cr 4.69TCr 358.59Cr 350.81Cr 15TCr EV / Sales 2026 *
2.12x
EV / Sales 2027 * 1.57x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day-0.24%
1 week-1.16%
Current month-3.35%
1 month-3.98%
3 months-8.11%
6 months-10.83%
Current year+2.55%
1 week 20.5
Extreme 20.495
21.45
1 month 20.23
Extreme 20.23
21.51
Current year 19
Extreme 19
25.14
1 year 16.52
Extreme 16.52
25.14
3 years 12.22
Extreme 12.22
25.14
5 years 10.64
Extreme 10.64
25.14
10 years 7.58
Extreme 7.58
25.14
Manager TitleAgeSince
Chief Executive Officer 42 20/05/2020
Director of Finance/CFO 60 21/08/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 75 12/02/2018
Director/Board Member 66 12/02/2018
Director/Board Member 42 19/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Tax

Controller/Auditor

-1,127 0.0015%
20/08/26 Tax

Chief Executive Officer

-1,130 0.0015%
20/08/26 Tax

Chief Financial Officer

-558 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-0.24%-1.16%+16.11%+58.06% 148.1Cr
-0.61%-3.43%+39.40%+112.31% 1,01900Cr
-1.02%-5.60%+37.67%+65.02% 62TCr
+1.11%-0.58%+11.10%+77.28% 46TCr
+0.34%-3.01%+61.21%+40.71% 36TCr
-0.95%-4.05%+21.60%+39.37% 33TCr
-1.46%-2.89%+11.84%+24.60% 27TCr
-1.35%-5.43%-4.69%+8.40% 24TCr
-1.04%-2.79%+35.52%+51.34% 22TCr
-1.87%-4.10%+30.92%+95.33% 18TCr
Average -0.24%-3.17%+26.07%+57.24% 36.99TCr
Weighted average by Cap. +0.42%-3.32%+30.51%+68.95%

Financials

2026 *2027 *
Net sales 45Cr 40Cr 37Cr 34Cr 64Cr 4.34TCr 65Cr 452.9Cr 175.5Cr 2.22TCr 169.44Cr 165.76Cr 7.12TCr 49Cr 44Cr 41Cr 37Cr 70Cr 4.71TCr 71Cr 491.76Cr 190.56Cr 2.41TCr 183.97Cr 179.98Cr 7.73TCr
Net income 18Cr 16Cr 15Cr 14Cr 26Cr 1.72TCr 26Cr 179.83Cr 70Cr 880.62Cr 67Cr 66Cr 2.83TCr 17Cr 16Cr 14Cr 13Cr 25Cr 1.68TCr 25Cr 175.14Cr 68Cr 857.67Cr 66Cr 64Cr 2.75TCr
Net Debt -53Cr -47Cr -44Cr -40Cr -75Cr -5.06TCr -76Cr -527.81Cr -204.53Cr -2.58TCr -197.46Cr -193.18Cr -8.3TCr -71Cr -63Cr -59Cr -54Cr -101.49Cr -6.84TCr -102.44Cr -714.5Cr -276.87Cr -3.5TCr -267.31Cr -261.5Cr -11TCr
Logo Innoviva, Inc.
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. Its royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, it is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. Its products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO, is for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in a Phase III clinical trial.
Employees
159
Date Price Change Volume
02/26/02 $20.50 -0.24% 7,74,706
01/26/01 $20.55 -3.11% 9,27,091
30/26/30 $21.21 +0.47% 11,00,217
29/26/29 $21.11 -0.57% 5,55,807
28/26/28 $21.23 +2.36% 8,54,634
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
20.50USD
Average target price
35.00USD
Spread / Average Target
+70.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INVA Stock